Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer

Article Abstract:

This trial demonstrated that the addition of radiation therapy to tomoxifen significantly decreased the rate of local relapse in women 50 years of age or older who had T1 or T2 node-negative breast cancer. 769 women with early breast cancer were randomly assigned to receive breast irradiation plus tamoxifen or tamoxifen alone. As compared with tamoxifen alone, radiotherapy plus tamoxifen significantly reduces the risk of breast and auxiliary recurrence after lumpectomy in women with small, node-negative, hormone-receptor-positive breast cancers.

Author: Fyles, Anthony W., McCready, David R., Manchul, Lee A., Trudeau, Maureen E., Merante, Patricia, R.N.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
Health aspects

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer

Article Abstract:

Radiation therapy significantly improves local control but not overall survival among women with breast cancer is observed. In women 70 years of age or older and who had clinical stage I, estrogen-receptor-positive breast carcinoma treated by lumpectomy, 636 women were randomly assigned to receive tamoxifen plus radiation therapy or tamoxifen alone. Lumpectomy plus adjuvant therapy with tamoxifen alone is a realistic choice for the treatment of women 70 years of age or older who have early estrogen-receptor-positive breast cancer.

Author: McCormick, Beryl, Cirrincione, Constance, Hughes, Kevin S., Schnaper, Lauren A., Berry, Donald
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
Science & research, Research, Lumpectomy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Risk and benefits of phase 1-oncology trials, 1991 through 2002

Article Abstract:

The Cancer Therapy Evaluation Program at the National Cancer Institute that sponsored a nonpediatric phase 1 oncology trails between 1991 and 2002 was reviewed. The rates of response of treatment, of stable disease, of grade 4 toxic events, and of treatment-related deaths were reported.

Author: Emanuel, Ezekiel J., McCabe, Mary S., Grady, Christine, Horstmann, Elizabeth, Yamamoto, Seiichiro, Budd, Troy, Grochow, Louise, Rubinstein, Larry, Shoemaker, Dale
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
United Kingdom, Labor Distribution by Employer, Mortality, Statistics, Cancer

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Diagnosis, Cancer research, Breast cancer, Radiotherapy, Oncology, Experimental
Similar abstracts:
  • Abstracts: Human fetal growth and organ development: 50 years of discoveries. Cardiac autonomic modulation in normal, high-risk, and in vitro fertilization pregnancies during the first trimester
  • Abstracts: Progressive prothrombotic state in women with advancing HIV disease. T-cell lymphoma in HIV-infected patients
  • Abstracts: The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi
  • Abstracts: Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future. Introduction
  • Abstracts: Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.